NXTC NextCure Inc.

8.27
-0.22  -3%
Previous Close 8.49
Open 8.38
52 Week Low 6.69
52 Week High 14.3999
Market Cap $228,347,560
Shares 27,611,555
Float 25,967,303
Enterprise Value $-12,458,899
Volume 272,007
Av. Daily Volume 243,659
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
NC410
Solid Tumors
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
NC318
Solid tumors
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
NC762
Solid tumors
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board (SAB). Ethan Shevach, M.D., will retire from the SAB. Drs. Lieping Chen, M.D., Ph.D., Mario Sznol, M.D., and Stephen Miller, Ph.D., will continue to serve on the SAB.

    "With the addition of three new members to our Scientific Advisory Board, NextCure is well-positioned for the next stage of scientific discovery and clinical development," said Solomon…

    BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board (SAB). Ethan Shevach, M.D., will retire from the SAB. Drs. Lieping Chen, M.D., Ph.D., Mario Sznol, M.D., and Stephen Miller, Ph.D., will continue to serve on the SAB.

    "With the addition of three new members to our Scientific Advisory Board, NextCure is well-positioned for the next stage of scientific discovery and clinical development," said Solomon Langermann, Ph.D., NextCure's chief scientific officer. "These individuals have impressive breadth and depth of clinical experiences across oncology and immunology and their counsel will be important for NextCure's current and future clinical programs. We would like to thank Dr. Shevach for valuable contributions to our SAB."

    • Professor Elizabeth Jaffee, M.D.

    Dr. Jaffee is Deputy Director of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, the Dana and Albert "Cubby" Broccoli Professor of Oncology at Johns Hopkins University and an international leader in immune based therapies. Dr. Jaffee's research is focused on the development of novel vaccine approaches that overcome immune tolerance to cancers, and she has completed multiple studies testing an allogeneic tumor vaccine in patients with pancreatic cancer. She also established Johns Hopkins' Cell Processing and Gene Therapy cGMP Facility, and currently holds six vaccine patents. Dr. Jaffee earned her M.D. from New York Medical College.

    • Professor Ursula Matulonis, M.D.

    Dr. Matulonis is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. Dr. Matulonis co-leads the Gynecologic Cancer Program within the Dana-Farber/Harvard Cancer Center and the Ovarian Cancer Specialized Program in Research Excellence (SPORE) grant from the National Cancer Institute. Her research is focused on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer. Dr. Matulonis earned her M.D. from the Albany Medical College.

    • Professor Weiping Zou, M.D., Ph.D.

    Dr. Zou is the Charles B. de Nancrede Professor; Professor of Pathology, Immunology, Biology and Surgery; Director of the Center of Excellence for Cancer Immunology and Immunotherapy; and Co-Director of the Cancer Hematopoiesis and Immunology Program at the University of Michigan School of Medicine and Rogel Cancer Center. Dr. Zou leads a multidisciplinary laboratory that investigates the human cancer microenvironment with the goal of understanding the nature of human tumor immune responses and developing mechanism-informed combination therapies for cancer. His laboratory has demonstrated that the interaction between tumor cells and the host immune system fosters tumor immunosuppressive networks and results in cancer progression and therapeutic resistance. Dr. Zou earned his M.D. from the Tongji Medical College in China and Ph.D. from the University of Paris in France.

    About NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com

    Cautionary Statement Regarding Forward-Looking Statements

    Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," "hope," "forward" and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure's plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

    Investor Inquiries

    Timothy Mayer, Ph.D.

    NextCure, Inc.

    Chief Operating Officer

    (240) 762-6486

    IR@nextcure.com



    Primary Logo

    View Full Article Hide Full Article
  2. BELTSVILLE, Md., Oct. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the online journal Frontiers in Immunology, which indicate that collagen fragments produced in cancer can mediate T cell suppression through LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells. This immune suppression could be reversed by LAIR-2, a natural decoy of LAIR-1, and NC410, a LAIR-2 fusion protein. NC410 is currently being evaluated in a Phase 1/2 clinical trial in patients with…

    BELTSVILLE, Md., Oct. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the online journal Frontiers in Immunology, which indicate that collagen fragments produced in cancer can mediate T cell suppression through LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells. This immune suppression could be reversed by LAIR-2, a natural decoy of LAIR-1, and NC410, a LAIR-2 fusion protein. NC410 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors and is a first-in-class immunomedicine designed to block LAIR-1-mediated immune suppression.

    "Collagen fragments, present in the tumor microenvironment and in circulation of certain cancer patients, mediate immune inhibition by binding to LAIR-1. High expression of collagen fragments and LAIR-1 correlate with worse disease outcomes and resistance to current immunotherapies," said Solomon Langermann, Ph.D., NextCure's chief scientific officer. "NC410, a LAIR-2 fusion protein, is able to block LAIR-1-mediated immune suppression which supports its potential as a valuable therapeutic option for patients who are resistant to current immunotherapies. We look forward to continuing the evaluation of NC410 in its ongoing Phase 1/2 clinical trial, for which we will report initial clinical data at the Society for Immunotherapy of Cancer conference in November."

    The publication, titled "Collagen fragments produced in cancer mediate T cell suppression through Leukocyte-Associated Immunoglobulin-like Receptor 1," details an analysis of historic datasets to evaluate the negative impact of collagen fragments and LAIR-1 expression in patients with cancer and new data demonstrating that collagen fragments can bind to and induce LAIR-1 immune suppression, which can be reversed by NC410.

    The paper was published in collaboration with Linde Meyaard, principal investigator at the Center for Translational Immunology, University Medical Center Utrecht, and an Oncode investigator at Oncode Institute.

    About NC410

    NC410 is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells, a type of antigen presenting cell. In preclinical research, it has been shown that LAIR-1 inhibits T cell function and myeloid activity. In preclinical studies, NC410 blocks the negative effects of LAIR-1 and promotes T cell function and myeloid cell activity. NextCure believes NC410 has the potential to treat multiple cancer types.

    About NC410 Phase 1/2 Clinical Study

    The NC410 Phase 1/2 study is a multi-center, first in human, open-label, single-armed study to determine the safety and tolerability, define maximum tolerated dose (MTD) and/or pharmacologically active dose, assess preliminary efficacy, and explore predictive and pharmacodynamic biomarkers of NC410 in patients with advanced or metastatic solid tumors. Phase 1 is a classic 3+3 dose escalation design to determine the safety, tolerability, MTD and recommended phase 2 dose (RP2D). Ongoing exploratory analyses include the assessment of predictive biomarkers associated with treatment benefit, and pharmacodynamic markers associated with study drug activity. Phase 2 is going to enroll NSCLC, cervical, colorectal, pancreatic, head and neck and other cancers depending on biomarker data available from the Phase 1 part of the study. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT04408599). 

    About NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. www.nextcure.com

    Forward-Looking Statements

    This press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regarding NextCure's expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "may," "will," "potential," "expects," "believes," "intends," "hope," "towards," "forward," "later" and similar expressions. Examples of forward-looking statements in this press release include, among others, statements about the development plans for NC410 and expected upcoming milestones, the potential benefits of NC410, and NextCure's plans, objectives and intentions with respect to the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts of the COVID-19 pandemic on NextCure's business, including NextCure's clinical trials, third parties on which NextCure relies and NextCure's operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure's limited operating history and no products approved for commercial sale; NextCure's history of significant losses; NextCure's need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on NextCure's FIND-IO™ platform; and dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including in Item 1A of NextCure's most recent Form 10-K and elsewhere in the Company's filings with the SEC. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

    Investor Inquiries

    Timothy Mayer, Ph.D.

    NextCure, Inc.

    Chief Operating Officer

    (240) 762-6486

    IR@nextcure.com



    Primary Logo

    View Full Article Hide Full Article
  3. BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to its Board of Directors.

    "I am thrilled to welcome two new members to NextCure's Board of Directors," said Michael Richman, NextCure's president and chief executive officer. "Both Dr. Feigal and Dr. Borgman bring extensive experience in clinical and biopharmaceutical settings. Their insights will be valuable as NextCure continues to advance multiple clinical programs and investigate and develop new immunomedicines…

    BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to its Board of Directors.

    "I am thrilled to welcome two new members to NextCure's Board of Directors," said Michael Richman, NextCure's president and chief executive officer. "Both Dr. Feigal and Dr. Borgman bring extensive experience in clinical and biopharmaceutical settings. Their insights will be valuable as NextCure continues to advance multiple clinical programs and investigate and develop new immunomedicines for cancer patients. These appointments follow the resignation of Stella Xu, Ph.D. from the board as previously announced. In addition, we would like to thank Stella Xu for her commitment and support in building NextCure."

    Dr. Feigal is currently a Partner and Head of the Biologics Practice at NDA Partners LLC, a life sciences consulting and contract development organization, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. Dr. Feigal is also adjunct faculty at the Sandra Day O'Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law. Her career includes over thirty years in clinical drug development, with roles spanning industry and academic medicine, including at the National Cancer Institute, where she served as Acting Director, Division of Cancer Treatment/Diagnosis during her tenure; Senior Vice President of Research and Development at the California Institute of Regenerative Medicine, and Executive Medical Director, global development at Amgen. She currently serves as a board member for Xencor. She earned her M.D. from the University of California, Davis, completed an internal medicine residency at Stanford University and a hematology/oncology fellowship at the University of California, San Francisco.

    Dr. Borgman is currently Vice President and Global Therapeutic Area Lead, Hematology-Oncology, at Jazz Pharmaceuticals, where she is responsible for global development of the company's oncology and hematology drugs, including four marketed products. Previously, Dr. Borgman was Vice President, Clinical Research & Development, at Exelixis, where she was a Clinical Lead in the global development for cabozantinib in oncology indications including renal cell, hepatocellular and thyroid carcinoma. Earlier she was Chief Medical Officer and Vice President of Hana Biosciences (Talon Therapeutics), where she oversaw all aspects of the company's drug development operations. In addition, Dr. Borgman has worked as Associate Chief Medical Officer at KaloBios Pharmaceuticals, and she was formerly a Global Development Head at Abbott Pharmaceuticals (now AbbVie) where she was responsible for the early drug development of the PARP inhibitor, antimitotic, and Bcl-2/Bcl-XL platforms. Dr. Borgman continues clinical involvement, as a Consulting Associate Professor at Stanford University School of Medicine's Stem Cell Transplant & Cell Biology program, and as a Clinical Associate at University of Chicago's Department of Pediatric Oncology and Stem Cell Research. Dr. Borgman completed her fellowship in pediatric hematology - oncology and stem cell transplant at UCLA David Geffen School of Medicine, trained in pediatrics at Texas Children's Hospital, Baylor College of Medicine, and earned her M.D. from Loyola University of Chicago's Stritch School of Medicine.

    About NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com

    Cautionary Statement Regarding Forward-Looking Statements

    Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," "hope," "forward" and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure's plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

    Investor Inquiries

    Timothy Mayer, Ph.D.

    NextCure, Inc.

    Chief Operating Officer

    (240) 762-6486

    IR@nextcure.com



    Primary Logo

    View Full Article Hide Full Article
  4. BELTSVILLE, Md., Oct. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two clinical studies and one research study will be presented during oral and poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Washington, D.C., and in a virtual platform on November 10-14, 2021. The data come from clinical studies evaluating NC318, a Siglec-15 antibody, and NC410, a LAIR-2 fusion protein, in patients with advanced/metastatic solid tumors. In addition, in collaboration with the National Cancer…

    BELTSVILLE, Md., Oct. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two clinical studies and one research study will be presented during oral and poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Washington, D.C., and in a virtual platform on November 10-14, 2021. The data come from clinical studies evaluating NC318, a Siglec-15 antibody, and NC410, a LAIR-2 fusion protein, in patients with advanced/metastatic solid tumors. In addition, in collaboration with the National Cancer Institute at the National Institutes of Health, non-clinical data will be presented from a research study evaluating NC410's impact on T cell activation, myeloid cell polarization and anti-tumor activity.

    Oral Presentation Details:

    Title: Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors

    Lead Author: Elaine Shum, NYU Langone Hospitals

    Abstract Number: 490

    Oral Session: Concurrent Rapid Oral Abstract Presentation Session: Clinical

    Session Date & Time: November 13, 2021, 12:45-1:45pm ET

    Presentation Time: November 13, 2021, 1:31-1:39pm ET

    Poster Presentations Details:

    Title: NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) fused to human IgG1 Fc is safe and tolerable with evidence of immune modulation in subjects with advanced solid tumors

    Lead Author: Han Myint, M.D., NextCure

    Abstract Number: 487

    Session Date & Time: November 12, 2021, 7:00am-8:30pm ET

    Title: Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization

    Lead Author: Lucas Horn, Ph.D., National Cancer Institute

    Abstract Number: 570

    Session Date & Time: November 13, 2021, 7:00am-8:30pm ET

    About NC318

    NC318 is a first-in-class immunomedicine against Siglec-15 (S15), a novel immunomodulatory target found on highly immunosuppressive cells called M2 macrophages in the tumor microenvironment and on certain tumor types including lung, ovarian and head and neck cancers. In preclinical research, it was observed that S15 promoted the survival and differentiation of suppressive myeloid cells and negatively regulated T cell function, allowing cancer to avoid immune destruction. In preclinical studies, NC318 blocked the negative effects of S15. NextCure believes NC318 has the potential to treat multiple cancer types.

    About NC410

    NC410 is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells, a type of antigen presenting cell. In preclinical research, it has been shown that LAIR-1 inhibits T cell function and myeloid activity. In preclinical studies, NC410 blocks the negative effects of LAIR-1 and promotes T cell function and myeloid cell activity. NextCure believes NC410 has the potential to treat multiple cancer types.

    About NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com

    Cautionary Statement Regarding Forward-Looking Statements

    Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," "hope," "forward" and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure's plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

    Investor Inquiries

    Timothy Mayer, Ph.D.

    NextCure, Inc.

    Chief Operating Officer

    (240) 762-6486

    IR@nextcure.com



    Primary Logo

    View Full Article Hide Full Article
  5. BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th.

    An audio webcast of the pre-recorded presentation will be available on the Investors section of the company's website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days.

    About NextCure, Inc.
    NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class…

    BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th.

    An audio webcast of the pre-recorded presentation will be available on the Investors section of the company's website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days.

    About NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com

    Cautionary Statement Regarding Forward-Looking Statements

    Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," "hope," "forward" and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure's plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

    Investor Inquiries

    Timothy Mayer, Ph.D.

    NextCure, Inc.

    Chief Operating Officer

    (240) 762-6486

    IR@nextcure.com



    Primary Logo

    View Full Article Hide Full Article
View All NextCure Inc. News